It has been reported that patients with anti-TRIM21 positive ASS who are anti-Jo-1 and/or anti-PL7 positive have a significantly increased risk of concomitant ILD and exhibit more severe myositis and lower survival rates (170, 171). Here, TRIM21 is linked to interstitial lung disease.